Prescient Therapeutics (ASX: PTX)
Investor Q&A
An update on Prescient’s strategy and upcoming milestones, with a focus on PTX-100.
In the session, Steven discussed:
- The journey of value creation for biotech companies, and why Prescient is on the cusp of a significant inflection point.
- Why the data from their PTX-100 Phase 1b trial is so promising.
- How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths.
- How their $18m cash position allows them to go deep into a Phase 2 trial.
Follow PTX
What is a 708 investor?
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement. Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
Reach provides Corporate Advisory Services, including managing investor communications on behalf of Prescient Therapeutics Limited and may receive fees for its services.
Past performance is not a reliable indicator of future performance.